Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Tuesday, September 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals has launched the AMVUTTRA® (vutrisiran) ‘Play by Play’ initiative, aimed at educating the public about transthyretin-mediated amyloidosis (ATTR-CM). This initiative features stories from former professional athletes and their care teams to highlight the often-missed signs of the condition. The goal is to promote early recognition of symptoms for better patient care.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of an educational initiative to raise awareness of ATTR-CM.
  • Involvement of former professional athletes adds credibility and relatability.
  • Focus on early recognition of symptoms can lead to better patient outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
ALN-4324
Phase 1 · Obese or Overweight Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,’ a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams who support them. Through personal stories and expert perspectives, ‘Play by Play’ aims to help people recognize the symptoms of ATTR-CM earlie

Frequently Asked Questions

What is the AMVUTTRA® ‘Play by Play’ initiative?

It is an educational initiative by Alnylam to raise awareness about ATTR-CM.

Who is featured in the ‘Play by Play’ initiative?

Former professional athletes living with ATTR-CM and their care teams.

What does the initiative aim to achieve?

It aims to help people recognize the symptoms of ATTR-CM early.

Why focus on former athletes for this initiative?

Their stories add credibility and relatability to the awareness campaign.

ShareAdd on Google
Tags: ALNY Alnylam Pharmaceuticals ATTR-CM vutrisiran educational initiative former athletes
Last updated: Sep 29, 2026

Biotech snapshot

Cash runway
$3308M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 1
Obese or Overweight Healthy Volunteers →

Catalyst track record

+36%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →